KAHR Medical Raises $500K From Hadasit Bio Holdings and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel

JERUSALEM--(BUSINESS WIRE)--KAHR Medical, a Hadasit Bio-Holdings (HBL) (TASE:HDST) portfolio company, announced today that it has raised $500 thousand from HBL and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel (OCS). KAHR Medical’s drug development pipeline is built around the ‘trans signal converter proteins (TSCP)’ technology, a novel drug technology invented by Professor Mark L. Tykocinski and licensed from the University of Pennsylvania. The financing will support further development of KAHR Medical’s product pipeline.